Search
for
Sort by
Research 661–690 of 1000+
- Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients
- Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature
- Biomedical applications of Janus membrane
- Frontal fibrosing alopecia shows robust T helper 1 and Janus kinase 3 skewing
- Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata
- Engineered Janus hydrogels: biomimetic surface engineering and biomedical applications
- Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
- Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
- Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta‐analysis
- The role of Janus kinase inhibitors in the treatment of alopecia areata: A systematic review
- The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature
- Janus kinase inhibition for the treatment of refractory frontal fibrosing alopecia: A case series and review of the literature
- Janus Kinase Inhibitors in Dermatology: Part 1 — General Considerations and Applications in Vitiligo and Alopecia Areata
- Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib
- Janus Kinase Inhibitors for Alopecia Areata
- Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase‐4 inhibitors
- Janus kinase inhibitors: An innovative treatment for alopecia areata
- Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
- Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
- Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
- Janus kinase inhibitors for alopecia areata
- Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study
- Janus Kinase Inhibitors against Other Biological Treatments in Alopecia Areata
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- Janus kinase inhibitors for alopecia areata: a review of clinical data
- A review of Janus kinase inhibitor use in scarring alopecia
- Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata
- At the crossroads of 2 alopecias: Androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors
- Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative review
- Evaluating dermatologists’ knowledge of and attitudes toward Janus kinase inhibitor therapy for the treatment of alopecia areata